HK1200709A1 - Pharmaceutical formulations of tnf-alpha antibodies tnf- - Google Patents
Pharmaceutical formulations of tnf-alpha antibodies tnf-Info
- Publication number
- HK1200709A1 HK1200709A1 HK15101176.7A HK15101176A HK1200709A1 HK 1200709 A1 HK1200709 A1 HK 1200709A1 HK 15101176 A HK15101176 A HK 15101176A HK 1200709 A1 HK1200709 A1 HK 1200709A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tnf
- pharmaceutical formulations
- alpha antibodies
- alpha
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN610MU2012 | 2012-03-07 | ||
IN1606MU2012 | 2012-05-30 | ||
IN3031MU2012 | 2012-10-17 | ||
PCT/IN2013/000129 WO2013164837A1 (fr) | 2012-03-07 | 2013-03-05 | Formulations pharmaceutiques d'anticorps anti-tnf-alpha |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1200709A1 true HK1200709A1 (en) | 2015-08-14 |
Family
ID=48901138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15101176.7A HK1200709A1 (en) | 2012-03-07 | 2015-02-04 | Pharmaceutical formulations of tnf-alpha antibodies tnf- |
Country Status (19)
Country | Link |
---|---|
US (3) | US10093728B2 (fr) |
EP (3) | EP3412310B1 (fr) |
JP (3) | JP2015509526A (fr) |
KR (2) | KR20160105535A (fr) |
CN (1) | CN104159614A (fr) |
AP (1) | AP2014007922A0 (fr) |
AU (1) | AU2013255413C1 (fr) |
BR (1) | BR112014021325A2 (fr) |
CA (1) | CA2866692A1 (fr) |
CL (1) | CL2014002316A1 (fr) |
EA (1) | EA201491644A1 (fr) |
HK (1) | HK1200709A1 (fr) |
MX (2) | MX363700B (fr) |
NZ (1) | NZ629261A (fr) |
PH (1) | PH12014501988B1 (fr) |
SG (2) | SG10201609982PA (fr) |
TR (1) | TR201810815T4 (fr) |
WO (1) | WO2013164837A1 (fr) |
ZA (1) | ZA201406414B (fr) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
EP2702077A2 (fr) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante |
NZ629261A (en) * | 2012-03-07 | 2017-08-25 | Cadila Healthcare Ltd | Pharmaceutical formulations of tnf-alpha antibodies |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
US20150150982A1 (en) * | 2012-06-12 | 2015-06-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
KR102238677B1 (ko) | 2012-09-07 | 2021-04-12 | 코히러스 바이오사이언시즈, 인코포레이티드 | 아달리무맙의 안정한 수성 제형 |
UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
CN104707146B (zh) * | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | 一种含有阿达木单抗的药物组合物 |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
CA2944330A1 (fr) * | 2014-04-02 | 2015-10-08 | Intas Pharmaceuticals Limited | Composition pharmaceutique liquide d'adalimumab |
ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
EP2946765B1 (fr) * | 2014-05-23 | 2016-08-31 | Ares Trading S.A. | Composition pharmaceutique liquide |
ES2607489T3 (es) * | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
US9821059B2 (en) * | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
HUP1400510A1 (hu) | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
US20170355729A1 (en) * | 2014-12-02 | 2017-12-14 | Biogen Ma Inc. | Methods and compositions for controlling antibody aggregation |
EP3053572A1 (fr) * | 2015-02-06 | 2016-08-10 | Ares Trading S.A. | Composition pharmaceutique liquide |
WO2016162819A1 (fr) | 2015-04-07 | 2016-10-13 | Lupin Limited | Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
AU2016350717B2 (en) | 2015-11-03 | 2023-08-10 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
US20190046641A1 (en) * | 2015-11-30 | 2019-02-14 | Medimmune, Llc | Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
SG11201804961UA (en) | 2015-12-30 | 2018-07-30 | Genentech Inc | Formulations with reduced degradation of polysorbate |
JP6738608B2 (ja) * | 2016-01-22 | 2020-08-12 | 田中貴金属工業株式会社 | クロマトグラフ媒体 |
GB201604124D0 (en) * | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
AU2017287743C1 (en) * | 2016-06-30 | 2020-10-01 | Celltrion Inc. | Stable liquid pharmaceutical preparation |
FR3054444A1 (fr) * | 2016-07-29 | 2018-02-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Composition orale d'anticorps anti-tnf alpha |
US11692027B2 (en) | 2016-09-28 | 2023-07-04 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
KR20180046888A (ko) * | 2016-10-28 | 2018-05-09 | (주)셀트리온 | 안정한 약제학적 제제 |
CN110114078B (zh) | 2016-12-28 | 2024-01-30 | Jcr制药股份有限公司 | 冷冻干燥制剂 |
JOP20190162A1 (ar) * | 2016-12-30 | 2019-06-27 | Biocad Joint Stock Co | تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني |
RU2665966C2 (ru) * | 2016-12-30 | 2018-09-05 | Закрытое Акционерное Общество "Биокад" | Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα |
JP7177777B2 (ja) * | 2017-01-11 | 2022-11-24 | セルトリオン, インク. | 安定した液体製剤 |
US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
EP3372241A1 (fr) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Composition pharmaceutique liquide |
EP3372242A1 (fr) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Composition pharmaceutique liquide |
MX2019010895A (es) * | 2017-03-16 | 2019-11-05 | Lg Chemical Ltd | Formulacion liquida de anticuerpo anti-tnf alfa. |
CN108686204A (zh) | 2017-04-07 | 2018-10-23 | 浙江海正药业股份有限公司 | 包含组氨酸缓冲体系的英夫利西单抗组合物 |
CN108686205B (zh) * | 2017-04-07 | 2021-12-10 | 海正生物制药有限公司 | 英夫利西单抗冻干制剂 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
JP2020530027A (ja) * | 2017-08-08 | 2020-10-15 | ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト | ヘモペキシン製剤 |
MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
CN110151988A (zh) * | 2018-02-11 | 2019-08-23 | 百奥泰生物制药股份有限公司 | 一种靶向治疗TNF-α相关疾病的人抗体制剂 |
CN110302377B (zh) * | 2018-02-11 | 2020-04-17 | 百奥泰生物制药股份有限公司 | 一种靶向治疗TNF-α相关疾病的人抗体制剂 |
AU2020225202B2 (en) | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
US20220042977A1 (en) * | 2020-08-04 | 2022-02-10 | ProStabilis, Inc. | Protein Solubility Screening Kits and Their Use |
MX2023002063A (es) * | 2020-08-20 | 2023-03-16 | Momenta Pharmaceuticals Inc | Glicoproteinas sialiladas. |
WO2022111547A1 (fr) * | 2020-11-24 | 2022-06-02 | The University Of Hong Kong | Formulations de poudre inhalées pour l'administration d'anticorps par voie respiratoire |
KR20240073051A (ko) * | 2021-09-16 | 2024-05-24 | 주식회사 에이프로젠 | 항-TNFα 항체를 포함하는 약제학적 조성물 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US609382A (en) | 1898-08-16 | Cotton-chopper | ||
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
HU228630B1 (en) | 1996-02-09 | 2013-04-29 | Abbott Biotech Ltd | Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity |
EP0852951A1 (fr) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux |
ATE454137T1 (de) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
WO2003072060A2 (fr) * | 2002-02-27 | 2003-09-04 | Immunex Corporation | Preparation de polypeptides |
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
KR20080098504A (ko) * | 2006-02-03 | 2008-11-10 | 메디뮨 엘엘씨 | 단백질 제제 |
JP5535623B2 (ja) * | 2006-06-30 | 2014-07-02 | アッヴィ バイオテクノロジー リミテッド | 自動注射装置 |
AR066016A1 (es) * | 2007-04-11 | 2009-07-15 | Alcon Res Ltd | Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
BR122018013284B1 (pt) | 2008-10-29 | 2022-03-03 | Ablynx N.V | Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab |
EP2358395A4 (fr) * | 2008-11-17 | 2013-11-20 | Hoffmann La Roche | Procédé et formulation pour réduire l'agrégation d'une macromolécule dans des conditions physiologiques |
CA2760185A1 (fr) | 2009-05-04 | 2010-11-11 | Abbott Biotechnology Ltd. | Formulations stables a concentration proteique elevee d'anticorps anti-tnf-alpha humain |
CA2789061A1 (fr) * | 2010-02-26 | 2011-09-01 | Henrik Parshad | Compositions stables contenant des anticorps |
ES2910305T3 (es) * | 2010-08-19 | 2022-05-12 | Zoetis Belgium S A | Anticuerpos anti-NGF y su uso |
EP2471554A1 (fr) | 2010-12-28 | 2012-07-04 | Hexal AG | Formulation pharmaceutique comprenant un médicament biopharmaceutique |
GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
NZ629261A (en) * | 2012-03-07 | 2017-08-25 | Cadila Healthcare Ltd | Pharmaceutical formulations of tnf-alpha antibodies |
US20150150982A1 (en) | 2012-06-12 | 2015-06-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
KR102238677B1 (ko) | 2012-09-07 | 2021-04-12 | 코히러스 바이오사이언시즈, 인코포레이티드 | 아달리무맙의 안정한 수성 제형 |
-
2013
- 2013-03-05 NZ NZ629261A patent/NZ629261A/en not_active IP Right Cessation
- 2013-03-05 SG SG10201609982PA patent/SG10201609982PA/en unknown
- 2013-03-05 BR BR112014021325A patent/BR112014021325A2/pt not_active Application Discontinuation
- 2013-03-05 KR KR1020167023263A patent/KR20160105535A/ko not_active Application Discontinuation
- 2013-03-05 AP AP2014007922A patent/AP2014007922A0/xx unknown
- 2013-03-05 MX MX2014010776A patent/MX363700B/es unknown
- 2013-03-05 TR TR2018/10815T patent/TR201810815T4/tr unknown
- 2013-03-05 EA EA201491644A patent/EA201491644A1/ru unknown
- 2013-03-05 CA CA2866692A patent/CA2866692A1/fr not_active Abandoned
- 2013-03-05 EP EP18162422.2A patent/EP3412310B1/fr active Active
- 2013-03-05 JP JP2014560526A patent/JP2015509526A/ja not_active Withdrawn
- 2013-03-05 US US14/383,533 patent/US10093728B2/en active Active
- 2013-03-05 EP EP21162387.1A patent/EP3912639A1/fr not_active Ceased
- 2013-03-05 SG SG11201405475UA patent/SG11201405475UA/en unknown
- 2013-03-05 KR KR1020147026991A patent/KR101730694B1/ko active IP Right Grant
- 2013-03-05 WO PCT/IN2013/000129 patent/WO2013164837A1/fr active Application Filing
- 2013-03-05 EP EP13742519.5A patent/EP2822591B1/fr not_active Revoked
- 2013-03-05 AU AU2013255413A patent/AU2013255413C1/en not_active Ceased
- 2013-03-05 CN CN201380012986.8A patent/CN104159614A/zh active Pending
-
2014
- 2014-08-29 CL CL2014002316A patent/CL2014002316A1/es unknown
- 2014-09-01 ZA ZA2014/06414A patent/ZA201406414B/en unknown
- 2014-09-05 PH PH12014501988A patent/PH12014501988B1/en unknown
- 2014-09-08 MX MX2019003716A patent/MX2019003716A/es unknown
-
2015
- 2015-02-04 HK HK15101176.7A patent/HK1200709A1/xx unknown
-
2016
- 2016-09-30 JP JP2016193572A patent/JP6416841B2/ja active Active
-
2018
- 2018-06-27 JP JP2018122044A patent/JP2018162295A/ja active Pending
- 2018-09-06 US US16/123,293 patent/US20190071496A1/en not_active Abandoned
-
2022
- 2022-08-18 US US17/890,866 patent/US20230047111A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1200709A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies tnf- | |
HK1255336A1 (zh) | 藥物製劑及其製備方法 | |
HK1212701A1 (zh) | 恩雜魯胺製劑 | |
HK1203812A1 (en) | Novel pharmaceutical formulations | |
EP2864361A4 (fr) | Régime posologique de composés de fusion | |
ZA201504408B (en) | Solution formulations of engineered anti-il-23p19 antibodies | |
HRP20180567T1 (hr) | Farmaceutski pripravak omeprazola | |
IL236465A0 (en) | Pharmaceutical composition for delayed release of active substances | |
HK1209339A1 (en) | Pharmaceutical formulations | |
IL227905A0 (en) | Toroidal pharmaceutical compositions | |
GB201211406D0 (en) | Pharmaceutical formulations | |
GB201211403D0 (en) | Pharmaceutical formulations |